U.S., March 17 -- ClinicalTrials.gov registry received information related to the study (NCT07472647) titled 'SYS6090 Combination Therapy in Advanced Lung Cancer' on Feb. 04.
Brief Summary: This is an open-label, multi-cohort, multicenter Phase Ib/II clinical study designed to evaluate the safety, tolerability, and efficacy of SYS6090 injection in combination with chemotherapy or chemotherapy and bevacizumab or SYS6010 (an EGFR ADC) in participants with advanced lung cancer.
Study Start Date: Feb. 28
Study Type: INTERVENTIONAL
Condition:
Non-Small Cell Lung Cancer
Small Cell Lung Cancer
Intervention:
DRUG: SYS6090 + pemetrexed + platinum-based chemotherapy
In this group, participants will receive SYS6090 in combination with pemetrex...